Cargando…
Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106192/ https://www.ncbi.nlm.nih.gov/pubmed/36723862 http://dx.doi.org/10.1097/CM9.0000000000002520 |
_version_ | 1785026375537655808 |
---|---|
author | Chai, Sanbao Yu, Shuqing Liu, Fengqi Liu, Zuoxiang Yang, Qingqing Sun, Feng |
author_facet | Chai, Sanbao Yu, Shuqing Liu, Fengqi Liu, Zuoxiang Yang, Qingqing Sun, Feng |
author_sort | Chai, Sanbao |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10106192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101061922023-04-17 Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model Chai, Sanbao Yu, Shuqing Liu, Fengqi Liu, Zuoxiang Yang, Qingqing Sun, Feng Chin Med J (Engl) Correspondence Lippincott Williams & Wilkins 2023-01-05 2023-02-01 /pmc/articles/PMC10106192/ /pubmed/36723862 http://dx.doi.org/10.1097/CM9.0000000000002520 Text en Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Correspondence Chai, Sanbao Yu, Shuqing Liu, Fengqi Liu, Zuoxiang Yang, Qingqing Sun, Feng Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model |
title | Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model |
title_full | Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model |
title_fullStr | Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model |
title_full_unstemmed | Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model |
title_short | Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model |
title_sort | benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106192/ https://www.ncbi.nlm.nih.gov/pubmed/36723862 http://dx.doi.org/10.1097/CM9.0000000000002520 |
work_keys_str_mv | AT chaisanbao benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel AT yushuqing benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel AT liufengqi benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel AT liuzuoxiang benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel AT yangqingqing benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel AT sunfeng benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel |